These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37688341)

  • 21. D-MELD, the Product of Donor Age and Preoperative MELD, Predicts Surgical Outcomes After Living Donor Liver Transplantation, Especially in the Recipients With HCV-positive and Smaller Grafts.
    Tanemura A; Mizuno S; Kato H; Murata Y; Kuriyama N; Azumi Y; Kishiwada M; Usui M; Sakurai H; Isaji S
    Transplant Proc; 2016 May; 48(4):1025-31. PubMed ID: 27320548
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved Graft Survival After Liver Transplantation for Recipients With Hepatitis C Virus in the Direct-Acting Antiviral Era.
    Cotter TG; Paul S; Sandıkçı B; Couri T; Bodzin AS; Little EC; Sundaram V; Charlton M
    Liver Transpl; 2019 Apr; 25(4):598-609. PubMed ID: 30716208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Negativization of viremia prior to liver transplant reduces early allograft dysfunction in hepatitis C-positive recipients.
    Martini S; Tandoi F; Terzi di Bergamo L; Strona S; Lavezzo B; Sacco M; Maione F; Gonella F; Strignano P; Dell Olio D; Salizzoni M; Saracco GM; Romagnoli R
    Liver Transpl; 2017 Jul; 23(7):915-924. PubMed ID: 28422425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Impact of Pre-Heart Transplantation Blood Transfusion Varies Based on Recipient MELD-XI Score.
    Nordan T; Lee HH; Chen FY; Couper GS; Kawabori M
    ASAIO J; 2024 Aug; 70(8):682-689. PubMed ID: 38446870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Kidney Transplantation From Hepatitis C Virus-Infected Donors to Uninfected Recipients: A Systematic Review for the KDIGO 2022 Hepatitis C Clinical Practice Guideline Update.
    Gordon CE; Adam GP; Jadoul M; Martin P; Balk EM
    Am J Kidney Dis; 2023 Oct; 82(4):410-418. PubMed ID: 37061019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liver transplantation from anti-hepatitis C virus-positive donors: our experience.
    Álvaro E; Abradelo M; Fuertes A; Manrique A; Colina F; Alegre C; Calvo J; García M; García-Sesma A; Cambra F; Sanabria R; Moreno E; Jimenez C
    Transplant Proc; 2012; 44(6):1475-8. PubMed ID: 22841188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Hepatitis C Virus Infection on Heart Transplants in the Current Era.
    Fujisaki T; Mikami T; Kuno T; Moss N; Itagaki S
    Transplantation; 2021 Nov; 105(11):2482-2489. PubMed ID: 33496557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
    Verna EC; Morelli G; Terrault NA; Lok AS; Lim JK; Di Bisceglie AM; Zeuzem S; Landis CS; Kwo P; Hassan M; Manns MP; Vainorius M; Akushevich L; Nelson DR; Fried MW; Reddy KR
    J Hepatol; 2020 Sep; 73(3):540-548. PubMed ID: 32243960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Use of Hepatitis C Virus-Positive Organs in Hepatitis C Virus-Negative Recipients.
    Kuntzen C; Bagha Z
    Clin Liver Dis; 2022 May; 26(2):291-312. PubMed ID: 35487612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The association of donor hepatitis C virus infection with 3-year kidney transplant outcomes in the era of direct-acting antiviral medications.
    Sutcliffe S; Ji M; Chang SH; Stewart D; Axelrod DA; Lentine KL; Wellen J; Alrata L; Gupta G; Alhamad T
    Am J Transplant; 2023 May; 23(5):629-635. PubMed ID: 37130619
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study.
    Bethea ED; Gaj K; Gustafson JL; Axtell A; Lebeis T; Schoenike M; Turvey K; Coglianese E; Thomas S; Newton-Cheh C; Ibrahim N; Carlson W; Ho JE; Shah R; Nayor M; Gift T; Shao S; Dugal A; Markmann J; Elias N; Yeh H; Andersson K; Pratt D; Bhan I; Safa K; Fishman J; Kotton C; Myoung P; Villavicencio MA; D'Alessandro D; Chung RT; Lewis GD
    Lancet Gastroenterol Hepatol; 2019 Oct; 4(10):771-780. PubMed ID: 31353243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current Use of Hearts From Hepatitis C Viremic Donors.
    Moayedi Y; Fan CPS; Gulamhusein AF; Manlhiot C; Ross HJ; Teuteberg JJ; Khush KK
    Circ Heart Fail; 2018 Dec; 11(12):e005276. PubMed ID: 30562093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list.
    Chhatwal J; Samur S; Kues B; Ayer T; Roberts MS; Kanwal F; Hur C; Donnell DM; Chung RT
    Hepatology; 2017 Mar; 65(3):777-788. PubMed ID: 27906468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of impaired hepato-renal function and liver fibrosis in patients admitted for acute heart failure.
    Kawahira M; Tamaki S; Yamada T; Watanabe T; Morita T; Furukawa Y; Kawasaki M; Kikuchi A; Kawai T; Seo M; Nakamura J; Kayama K; Kimura T; Ueda K; Sakamoto D; Kogame T; Ito S; Chang Y; Fukunami M
    ESC Heart Fail; 2021 Apr; 8(2):1274-1283. PubMed ID: 33472273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liver, simultaneous liver-kidney, and kidney transplantation from hepatitis C-positive donors in hepatitis C-negative recipients: A single-center study.
    Crismale JF; Khalid M; Bhansali A; De Boccardo G; Khaim R; Florman SS; Shapiro R; Schiano TD
    Clin Transplant; 2020 Jan; 34(1):e13761. PubMed ID: 31808193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Balancing donor and recipient risk factors in liver transplantation: the value of D-MELD with particular reference to HCV recipients.
    Avolio AW; Cillo U; Salizzoni M; De Carlis L; Colledan M; Gerunda GE; Mazzaferro V; Tisone G; Romagnoli R; Caccamo L; Rossi M; Vitale A; Cucchetti A; Lupo L; Gruttadauria S; Nicolotti N; Burra P; Gasbarrini A; Agnes S;
    Am J Transplant; 2011 Dec; 11(12):2724-36. PubMed ID: 21920017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatorenal dysfunction assessment with the Model for End-Stage Liver Disease Excluding INR score predicts worse survival after heart transplant in pediatric Fontan patients.
    Amdani S; Simpson KE; Thrush P; Shih R; Simmonds J; Knecht K; Mogul DB; Hurley K; Koehl D; Cantor R; Naftel D; Kirklin JK; Daly KP
    J Thorac Cardiovasc Surg; 2022 Apr; 163(4):1462-1473.e12. PubMed ID: 33745714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes of Over 1000 Heart Transplants Using Hepatitis C-Positive Donors in the Modern Era.
    Kwon JH; Hill MA; Patel R; Tedford RJ; Hashmi ZA; Shorbaji K; Huckaby LV; Welch BA; Kilic A
    Ann Thorac Surg; 2023 Feb; 115(2):493-500. PubMed ID: 36368348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Should organs from hepatitis C-positive donors be used in hepatitis C-negative recipients for liver transplantation?
    Selzner N; Berenguer M
    Liver Transpl; 2018 Jun; 24(6):831-840. PubMed ID: 29624894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: an open-label, single-centre, pilot trial.
    Cypel M; Feld JJ; Galasso M; Pinto Ribeiro RV; Marks N; Kuczynski M; Kumar D; Bahinskaya I; Bagnato VS; Kurachi C; Slutsky AS; Yeung JC; Donahoe L; de Perrot M; Yasufuku K; Pierre A; Binnie M; Chaparro C; Martinu T; Chen M; Tikkanen J; Chow CW; Sidhu A; Waddell TK; Keshavjee S; Singer LG; Humar A
    Lancet Respir Med; 2020 Feb; 8(2):192-201. PubMed ID: 31606437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.